Purpose of review Our understanding of critical illness is transforming as we develop a better understanding of the impact pathogen-associated molecular patterns and damage-associated molecular patterns (DAMPs) have on the pathogenesis of disease. Of the known DAMPs, there is a growing interest in mitochondrial DNA (mtDNA) as a DAMP capable of propagating the inflammatory response seen in sepsis and other conditions. In this review, we describe the varying mechanisms by which mtDNA is translocated from mitochondria into cytosol and the extracellular space where it can illicit an inflammatory response. In addition, we present some of the most recent clinical studies to examine mtDNA in critical illness.
INTRODUCTION
The endosymbiotic theory of mitochondria postulates that over a billion years ago energy-producing alpha-bacteria were either engulfed by or invaded archezoan cells [1] . This ancient encounter resulted in a symbiotic relationship between eukaryotic cells and eubacteria [1] that facilitated the evolution of eukaryotic cells by providing them with compartmentalized bioenergetic and biosynthetic factories.
To date, much of the research on mitochondria has focused on their role as cellular organelles responsible for energy production, protein synthesis, catabolism, and cell death [2, 3] . However, there has been a growing interest in mitochondrial DNA (mtDNA) as a potential damage-associated molecular pattern (DAMP) [4, 5] . The 'Danger Model' stipulates that when cells are injured or dying, irrespective of the stimulus, they release their components into the extracellular space, which in turn drives an immune or inflammatory response [5] . Examples of known DAMPs include DNA, highmobility group box 1, or heat shock proteins [6] .
When the Danger Model is considered alongside the endosymbiotic model it raises the question of whether or not mitochondria can affect the pathogenesis of disease. Like bacteria, mitochondria possess DNA containing unmethylated CpG [4, 7] and formylated peptides [8, 9] -molecules known to exert potent immune responses through Toll-like receptor 9 (TLR9) or formyl peptide receptors, respectively. Studies of human mitochondria have illustrated polymorphonuclear leukocyte chemotaxis can be induced by disrupting mitochondrial membranes with detergent or sonication [9] . Taken together, this information suggests mitochondrial components can regulate immune responses to stressors and stimuli [5, 10] .
Of the known mitochondrial DAMPs, the one that has garnered the most interest is mtDNA [4, 11] . There is a growing body of literature suggesting mtDNA is not only released in the setting of critical illness [12 && ,13] but can also propagate the inflammatory response through its interaction with the immune system [4, 5, 11] . This is of particular interest as it raises the possibility that mtDNA may function as a surrogate of disease severity or even a predictor of mortality in critically ill patients.
Herein, we will discuss the scientific evidence supporting mtDNA as a DAMP that is important in disease pathogenesis as well as well as the most recent clinical trials that investigated mtDNA in critically ill patients.
MITOCHONDRIAL DNA: FUNCTION AND REGULATION
MtDNA is a circular molecule of 16 569 bp encoding for 37 genes in humans [14] . Despite representing a very small portion of the DNA possessed by eukaryotic cells, mtDNA is essential as it codes for several key proteins of the oxidative phosphorylation system [2] . Although the importance of mtDNA extends beyond what is merely encoded by its nucleotide sequence as evidence suggests mtDNA is involved in cellular immune functions [4] . This involvement appears to be mediated by mtDNA leaving the confines of mitochondria to enter other cellular or extracellular compartments, in which it can subsequently trigger or promote immune responses by being recognized as a DAMP [4] .
Release of mitochondrial DNA from mitochondria to cytosol and extracellular compartments Multiple in-vitro and in-vivo studies have suggested mitochondrial membrane permeability transition (MPT) as the mechanism of mtDNA translocation from mitochondria to cytosol (Fig. 1) [15, 16] . When cells (e.g., macrophages) are exposed to pathogenassociated molecular patterns and/or DAMPs, the cells increase the generation of mitochondrial reactive oxygen species (ROS) [16, 17] . Increased mitochondrial ROS generation can decrease mitochondrial membrane potential, leading to impairment of membrane integrity [16, 18, 19] . These changes could subsequently permit leakage of mtDNA into cytosol [16, [19] [20] [21] . Inhibition of MPT by cyclosporine A and scavenging mitochondrial ROS by MitoTEMPO is known to prevent leakage of mtDNA into cytosol and the downstream immune response [15, 16] .
Another possible mechanism of mtDNA translocation within cells is destabilized mtDNA packaging [22] . MtDNA is packaged and stabilized by binding to transcription factor A, mitochondrial (TFAM) inside the mitochondrial inner membrane. Deficiency of TFAM causes aberrant mtDNA packaging promoting escape of mtDNA into cytosol [22] .
One of the proposed mechanisms by which mtDNA is translocated to the extracellular space is via necroptosis, a newly discovered form of programed necrosis (Fig. 1) [23, 24] . Necroptosis is driven by defined molecular pathways and has been implicated in various immune functions and inflammatory diseases [23, 24] . Evidence supporting this theory is derived from a study in mice in which blood transfusions were shown to increase the levels of extracellular mtDNA by induction of endothelial cell necroptosis [25] . The investigators of this study also showed an association between mtDNA and transfusion-related lung injury [25] . However, it remains unclear whether other types of cell death can also promote mtDNA release [26] .
Platelets are another potential source of extracellular mtDNA. Platelets are activated in inflammatory conditions, including sepsis, where they secrete granules as well as thrombotic and proinflammatory membrane vesicles termed microparticles [27, 28] . A recent study suggests platelets also secrete their mitochondria upon activation [29] . Once in the extracellular space, mitochondrial membrane phospholipids may be hydrolyzed by serum secretory phospholipase A2-IIa thereby releasing mtDNA [29] .
Functions of mitochondrial DNA as a damage-associated molecular pattern TLR9 was initially discovered as an innate immune receptor capable of recognizing bacteria or viruses by binding unmethylated CpG motiffs within their DNA [30, 31] . However, the endosymbiotic theory of mitochondria means mtDNA can also be recognized by TLR9 and trigger an innate immune response ( Fig. 1 ). This has been illustrated in vivo in which the administration of mtDNA in mice can induce acute lung injury [32] or activate TLR9, leading to the development of atherosclerosis [33] and kidney injury [34] . Animal models of nonalcoholic KEY POINTS mtDNA is a DAMP capable of propagating an immune response through its interaction with Toll-like receptor 9 and inflammasomes. mtDNA is elevated in critically ill patients.
Clinical trials provide conflicting evidence about whether or not mtDNA is associated with mortality in critically ill patients.
steatohepatitis have further implicated mtDNA as a DAMP by illustrating it can influence the severity of liver injury through a TLR9-mediated inflammatory response [35] . Furthermore, a recent investigation into the relationship between TLR9 and mtDNA in critically ill patients found mtDNA to be significantly associated with mortality in patients with high intracellular expression of TLR9 [hazard ratio, 2.3; 95% confidence interval (CI), 1.1-4.8;
. These studies imply that mtDNA can be implicated in the pathogenesis of diseases via TLR9-mediated immune responses.
Another important mechanism by which mtDNA triggers an immune response is through interaction with inflammasomes, which are multiprotein complexes that modulate inflammatory responses through caspase-1 activation and secretion of proinflammatory cytokines (i.e., IL-1ß and IL-18) (Fig. 1) [36] . Cytosolic mtDNA has been shown to have a synergistic effect on inflammasome activation by enhancing caspase-1 activation as well as the secretion of IL-1ß and IL-18 [4, 16, 21] . Interestingly, depletion of mtDNA in macrophages impairs inflammasome activation in macrophages, suggesting a critical role of mtDNA in the immune response [16] .
Previous studies in critically ill patients have shown elevated levels of cell-free circulating mtDNA and plasma IL-18 are associated with disease severity and mortality [13, 37] . This suggests mtDNA may have a role in the pathogenesis of inflammation and tissue injury via its ability to drive IL-18 production through inflammasomes or even directly.
Elimination and degradation of mitochondrial DNA
Given the potential roles of mtDNA on inflammation, it is also important mechanisms exist to regulate or remove excess deviated mtDNA. At the Recent studies suggest that cell-free mitochondrial DNA (e.g., in plasma) can be measured and used as a biomarker to predict prognosis of critically ill patients.
cellular level autophagy, an intracellular degradation system that delivers cytoplasmic constituents to the lysosome [38] , can uptake and digest damaged mitochondria before they release mtDNA ( Fig. 1 ) [16] . Once mtDNA is translocated to cytosol, mtDNA can be degraded by intracellular deoxyribonuclease (DNase) (Fig. 1) . Among reported isoforms of DNase, DNase II has been shown to localize in lysosome and digest cytosolic mtDNA escaped from autophagy-mediated degradation [39] . Deficiency of DNase II displays accumulation of mtDNA deposits in autolysosomes and infiltration of inflammatory cells in a preclinical model of heart failure [39] .
Although it remains unclear how circulating cellfree mtDNA is eliminated, it has been shown that liver endothelial cells can also uptake circulating ds DNA [40] . In addition, mtDNA is detectable in urine, suggesting kidneys can also regulate the elimination of mtDNA from circulating blood [41] .
MITOCHONDRIAL DNA IN CRITICALLY ILL PATIENTS
Given the function of mtDNA as a DAMP, there has been a growing interest in mtDNA as a predictor of disease severity and/or mortality in critically ill patients. In 2013, Nakahira et al. published one of the first clinical trials to investigate this subject [13] . For their study, the investigators enrolled 200 medical ICU patients into a primary cohort. They found mtDNA to be significantly higher in patients who died within 28 days of ICU admission than in survivors (median 9504 vs. 1927 copies/ml,
). Furthermore, the odds of dying within 28 days of ICU admission was found to increase with each log 10 -unit increase in mtDNA (odds ratio 1.9, 95% CI 1.5-2.4, P ¼ 2 Â 10 -7
). These findings were replicated within a validation cohort of 243 critically ill patients with acute respiratory distress syndrome. Their data also suggested a mtDNA level of 3200 copies/ml may allow physicians to discriminate between patients who are at a high vs. low of death because the addition of this value to a clinical model improved the area under the receiver operating characteristic curve (AUROCC) for mortality from 0.76 to 0.83.
Since 2013, several studies have attempted to replicate or expand upon the findings of Nakahira et al. Over the past 2 years alone, there have been five studies that examined mtDNA in critically ill adults who were admitted to a medical or cardiac ICU. The results of those studies will be discussed below.
In 2015, Bhagirath et al. published a translational study aimed at elucidating the role of nuclear DNA (nucDNA), mtDNA, and bacterial DNA (bacDNA) in sepsis [42] . The clinical portion of their study consisted of measuring plasma nucDNA and plasma mtDNA in 12 consecutive patients admitted to an ICU with severe sepsis. Within this cohort, the levels of plasma nucDNA and plasma mtDNA were greater than healthy controls by 200 and 50-fold, respectively. Recognizing the quantity and quality of a stimulus are not necessarily related, Bhagirath et al. performed a follow-up in-vivo experiment measuring the effect of varying levels of nucDNA, mtDNA, and bacDNA on the viability of neutrophils. Their focus on neutrophil viability stemmed from previous studies that illustrated delayed neutrophil apoptosis and their local accumulation in septic patients was associated with worse outcomes [43, 44] . They conducted this experiment by incubating neutrophils for 16-h with 1 and 15 mg/ml of the varying nucleic acids to reflect systemic and local conditions. What they found was the high concentration of mtDNA and both concentrations of bacDNA increased neutrophil viability. This was in stark contrast to nucDNA in which neither the low nor the high concentration had an impact on neutrophil viability.
A few months later, Krychtiuk et al. [12 && ] published a prospective, observational study examining mtDNA in 228 critically ill patients; this cohort was rather heterogeneous as it enrolled critically ill surgical patients (cardiothoracic) and medical ICU patients (68% of the cohort). They found the levels of plasma mtDNA in critically ill medical patients (24.1; interquartile range (IQR), 10.7-42.6 ng/ml) to be significantly higher than their healthy counterparts (13.8; IQR, 6.5-28.5 ng/ml; P < 0.05). Furthermore, within the medical population, they noted the highest levels of mtDNA were found within patients experiencing sepsis (33.2; IQR, 17.3-62.0 ng/ml) or cardiogenic shock (29.8; IQR, 17.2-53.6 ng/ml). Contrary to the medical patients, the levels of mtDNA in the surgical patients were virtually identical to healthy controls (P ¼ 0.82). Despite finding a statistically significant elevation in mtDNA the investigators did not find an association between mtDNA and the use of vasopressors, the need for mechanical ventilation, renal dysfunction, or disease severity scores (APACHE II, SAPS II, SOFA). However, they did note that significantly higher median levels of mtDNA were seen in patients who died within 30-days of ICU admission independent of demographics, primary diagnosis, and APACHE II score. They also observed mtDNA was significantly associated with mortality in medical patients (27.2, IQR ¼ 12.5-60.6 ng/ml vs. 21.1, IQR ¼ 9.6-37.2 ng/ml; P < 0.05), but not surgical patients (4.4, IQR ¼ 3.3-74.5 ng/ml vs. 13.6, IQR ¼ 8.8-29.9 ng/ml; P ¼ 0.20). Lastly, they calculated the AUROCC for mtDNA and a clinical model (involving APACHE II and sex) to be 0.6 and 0.79, respectively. When they added mtDNA to the clinical model, the AUC further improved to 0.81, which was statistically significant.
To explore the relationship between plasma nucDNA, plasma mtDNA, and various inflammatory markers (TNF-a, IL-6, IL-8, IL-10, and IL-1RA), Timmermans et al. [45] conducted a prospective observational study by collecting samples from ICU Day 1, 3, 5, 6, 9, 14, 21, and 28 in 121 patients with septic shock. Their data showed the levels of nucDNA, mtDNA, and inflammatory cytokines to be significantly elevated and remain elevated at all time points in septic patients relative to healthy controls; however, the fold change seen in mtDNA was far less than what was seen in nucDNA for the septic shock cohort -reminiscent of what was observed by Bhagirath et al. Their data also noted a statistically significant correlation between plasma nucDNA and inflammatory cytokines during the first few days of shock, norepinephrine dose, and markers of end-organ damage (creatinine and total bilirubin). Although statistical significance could be found between plasma mtDNA and a few parameters, no conclusive patterns emerged over time. Another interesting observation made by the Timmermans study is that there was no discernable difference in the levels of nucDNA and mtDNA in patients with a history of cancer or autoimmune disease relative to those without such medical conditions. This is significant because it suggests conditions with a high degree of cell turn-over do not significantly alter mtDNA levels. If true, conditions like cancer may not limit mtDNA's promise as a biomarker as previously thought. However, further work is needed to substantiate this observation.
Adding to the growing body of literature on mtDNA in sepsis, Schäfer et al. [46] collected blood from 165 patients with 24 h of being diagnosed with severe sepsis. Not only was serum mtDNA significantly elevated in septic patients relative to controls (D-Loop, 76-fold increase; ATPase 6, 123-fold increase; all P < 0.0001), but they also found a significant difference in the levels of mtDNA between patients who died within 30 days of ICU admission and those who survived (D-Loop, 1.6 fg/ml AE 3.6 vs. 0.4 fg/ml AE 1.2; P ¼ 0.003; ATPase 6, 1.3 fg/ml AE 3.4 vs. 0.55 fg/ml AE 2.3; P ¼ 0.005). Like the Bhagirtah study, Schafer et al. were curious about the potential inflammatory effects of mtDNA, so they incubated human monocytes from the THP-1 cell line with 1 mg/ml of mtDNA. They found mRNA expression of TNF-a, IL-1ß, and hypoxia-inducible factor-1a was increased after the incubation period.
Although clinical investigators have primarily focused on mtDNA in patients with sepsis or trauma, Omura et al. [47] chose to study mtDNA and highmobility group box 1 (HMGB-1) in patients with postcardiac arrest syndrome. For the sake of brevity, the results of HMGB-1 will not be discussed as it is outside the scope of this review. Their patient population consisted of adults who obtained return of spontaneous circulation (ROSC) after sustaining an out-of-hospital cardiac arrest; individuals who suffered an arrest secondary to trauma had a DNR, a Glasgow Coma Scale score more than 8 upon arrival, or a primary brain disorder were excluded. This led to the enrollment of 21 patients, out of 195 screened, over an 18-month period. Once enrolled, samples were collected at arrival in addition to Day 2, 3, 5, and 7 post-ROSC. They found plasma mtDNA to be significantly higher on Day 1 relative to Day 2, 3, 5, and 7 (P < 0.001). Despite being able to find a measurable difference in mtDNA, they did not find a statistically significant association between mtDNA and time until ROSC (r ¼ 0.108, P ¼ 0.651), APACHE II (r ¼ À0.315, P ¼ 0.559), neurological outcome, and various other clinical parameters. To further assess the prognostic ability of mtDNA, they generated a ROC curve wherein they calculated the AUC to be 0.573. There are, however, several key points to be further addressed that may account for the variance between study results. The first is the lack of protocol standardization for the measurement of cell-free mtDNA. Although most studies utilized plasma for mtDNA measurement one used serum (Table 1 ). In addition, the proper preparation of plasma has yet to be established. This is significant because the presence or absence of platelets in the sample may artificially elevate the level of mtDNA if they are injured during the freeze-thaw process, leading to the release of mitochondria. Another consideration is that recent studies suggest a significant portion of plasma mtDNA is fragmented and very short (less than 100 bp). It is possible that the methods used in many studies (quantitative PCR) may not amplify this type of mtDNA. Finally, there is also the question of the appropriate patient population -it is conceivable that the mechanism driving mtDNA release differs in patients with cellular injury from sepsis and those with a mechanical injury as seen in patients posttrauma or postsurgery.
CONCLUSION
In this review, we discuss the functions and molecular regulation of mtDNA as a DAMP in addition to some of the most recent studies investigating mtDNA in critically ill patients. All of the studies presented illustrate that circulating mtDNA is elevated in critically ill patients. However, it remains unclear whether this elevation in mtDNA results from the severity of illness alone or whether mtDNA actively contributes to disease pathogenesis through interaction with TLR9 or inflammasomes [13] . Additional studies are needed to explore the role of mtDNA in critically ill patients and determine if mtDNA has promise as a biomarker of disease severity or mortality in critical illness.
